Clinical trial
Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma
NCT00297258 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00297258 |
|---|---|
| Title | Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma |
| Official title | Phase II Study of GW786034 in Patients With Relapsed or Refractory Soft Tissue Sarcoma |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sarcoma, Soft Tissue |
| Intervention type | Drug |
| Interventions | pazopanib |
| Enrollment | 148 |
| Start date | Nov 1, 2005 |
| Primary completion | Feb 1, 2014 |
| Completion | Feb 1, 2014 |
| First posted | Feb 28, 2006 |
| Last update posted | Feb 3, 2016 |
| Countries | Belgium, France, Hungary, Netherlands, United Kingdom |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: